106984-91-2

Usage

Uses

Used in Pharmaceutical Synthesis:
2-HYDROXY-5-FORMYLPYRIDINE is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs. Its presence in the molecular structure can influence the properties and effectiveness of the final product.
Used in Agrochemical Production:
In the agrochemical industry, 2-HYDROXY-5-FORMYLPYRIDINE is used as a key component in the creation of various agrochemicals. Its role is crucial in formulating products that can enhance crop protection and yield.
Used in Dye Manufacturing:
2-HYDROXY-5-FORMYLPYRIDINE is utilized in the production of dyes, where its chemical properties contribute to the color and stability of the dyes produced.
Used in Organic Chemistry Research:
Due to its unique structure, 2-HYDROXY-5-FORMYLPYRIDINE is used in the field of organic chemistry for research purposes. It serves as a valuable compound for exploring new chemical reactions and discovering novel materials.
Used in Material Science:
2-HYDROXY-5-FORMYLPYRIDINE is employed in material science for the development of new materials with specific properties. Its versatility in chemical reactions allows for the creation of materials with tailored characteristics for various applications.

InChI:InChI=1/C6H5NO2/c8-4-5-1-2-6(9)7-3-5/h1-4H,(H,7,9)

Upstream product

• 65873-72-5 6-methoxy-3-pyridinecarboxaldehyde 
• 18327-02-1 2-oxo-2H-pyran-5-carbaldehyde 
• 624-28-2 2,5-dibromopyridine 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 635712-99-1 6-benzyloxypyridine-3-carboxaldehyde 
• 95652-83-8 5-(dimethoxymethyl)-2-methoxypyridine 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 114951-35-8 3-pyridinecarbaldehyde diacetate 1-oxide 
• 114951-44-9 3-pyridine carbaldehyde diacetate 
• 884495-36-7 6-chloro-2-methylpyridine-3-carbaldehyde 

Downstream Products

• 230648-43-8 1-ethyl-6-oxo-1,6-dihydropyridine-3-carbaldehyde 
• 709044-98-4 3-(4-fluoro-3-trifluoromethyl-phenyl)-2-(6-oxo-1,6-dihydro-pyridin-3-yl)-2,3-dihydro-1H-quinazolin-4-one 
• 109205-68-7 5-(hydroxymethyl)-1,2-dihydropyridin-2-one 
• 1026516-86-8 5-[3-(4-methanesulfonyl-phenyl)-3H-imidazol-4-yl]-pyridin-2-ol 
• 1211577-99-9 6-(difluoromethoxy)nicotinaldehyde 

Relevant academic research and scientific papers

Pyridone derivatives carrying radical moieties: Hydrogen-bonded structures, magnetic properties, and metal coordination

Pyridone derivatives carrying radical moieties were prepared, namely a nitronyl nitroxide derivative 5-(4′,4′,5′,5′- tetramethylimidazoline-3′-oxide-1′-oxyl)-2(1H)-pyridone (1) and a verdazyl derivative 1,5-dimethyl-3-[2(1H)-pyridone]-6-oxoverdazyl (2). In the solid state, 1 and 2 form, via N-H?O intermolecular hydrogen bonds between the pyridone moieties, a zigzag one-dimensional chain structure and a cyclic dimer structure, respectively. These compounds exhibit antiferromagnetic intermolecular interactions. Mononuclear metal complexes [M(hfac) 2(1)2] (M = CuII, MnII; hfac = bis(hexafluoroacetylacetonate)) were prepared in which trans-[M(hfac) 2] are coordinated with the carbonyl oxygen of the pyridone ligands. Cyclic hydrogen bonds between the mononuclear units result in the formation of one-dimensional chains. Small antiferromagnetic (for CuII) and ferromagnetic (for MnII) exchange interactions between the metal ion and the ligands were observed.

COT MODULATORS AND METHODS OF USE THEREOF

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS

Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Selected anthranilaminde pyridinamides and their use as pharmaceutical agents

Selected anthranilamide pyridinamines of general formula I in which R1 and R2 have the meanings that are indicated in the description, as VEGFR-2 and VEGFR-3 inhibitors, their production and use as pharmaceutical agents for treating

ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE

The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more

Electrochemical versus anionic oxygenation of azathymine derivatives

Pymetrozine (1) was converted to hemiaminal 2 in low to moderate yield by trapping its dianion with oxygen followed by reduction with ferrous salts. Pymetrozines 18 and 19 failed to undergo this type of oxygenation. All three pymetrozines were oxidized electrochemically at C5 to methyl hemiaminals 20, 21, and 22, respectively. Hydrolysis of 20 to 2 was accomplished under either acid- or base-catalyzed conditions in excellent yields, whereas the hydrolysis of methyl hemiaminals 21 and 22 was best performed under basic conditions. Soil metabolites of pymetrozine 1, hemiaminals 2 and 3, were prepared on a medium scale and in excellent yields. Linear sweep voltammetry data and conditions for preparative-scale electrochemistry are furnished for the precursory pymetrozines. Complete experimental and spectral data are provided for all new compounds, and the relative merits of anionic versus electrochemical oxidations for alkyl amides are discussed. A cautionary note is provided with the description of the conditions for large-scale anionic oxygenation because of potential explosive hazards.